Modern management of uterine fibroids

References

• Solomon LA, Schimp VL, Ali-Fehmi R, Diamond MP, Munkarah AR. Clinical update of smooth muscle tumors of the uterus. J Minim Invasive Gynecol. 2005; 12: 401–8
   PubMed Web of Science ®Google Scholar
• Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: Abdominal myomectomy and hysterectomy. Clin Obstet Gynecol. 2001; 44: 385–400
   PubMed Web of Science ®Google Scholar
• Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003; 188: 100–7
   PubMed Web of Science ®Google Scholar
• Frishman GN, Jurema MW. Myomas and myomectomy. J Minim Invasive Gynecol. 2005; 12: 443–56
   PubMed Web of Science ®Google Scholar
• Martin Chaves EB, Brum IS, Stoll J, Capp E, Corleta HE. Insulin-like growth factor 1 receptor mRNA expression and autophosphorylation in human myometrium and leiomyoma. Gynecol Obstet Invest. 2004; 57: 210–3
   PubMed Web of Science ®Google Scholar
• Arici A, Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000; 73: 1006–11
   PubMed Web of Science ®Google Scholar
• Luo X, Ding L, Xu J, Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology. 2005; 146: 1097–118
   PubMed Web of Science ®Google Scholar
• Shikora SA, Niloff JM, Bistrian BR, Forse RA, Blackburn GL. Relationship between obesity and uterine leiomyomata. Nutrition. 1991; 7: 251–5
   PubMed Web of Science ®Google Scholar
• Day Baird D, Dunson DB. Why is parity protective for uterine fibroids?. Epidemiology. 2003; 14: 247–50
   PubMed Web of Science ®Google Scholar
• Wallach EE, Vlahos NF. Uterine myomas: An overview of development, clinical features, and management. Obstet Gynecol. 2004; 104: 393–406
   PubMed Web of Science ®Google Scholar
• Somigliana E, Vercellini P, Daguati R, Pasin R, De GO, Crosignani PG. Fibroids and female reproduction: A critical analysis of the evidence. Hum Reprod Update. 2007; 13: 465–76
   PubMed Web of Science ®Google Scholar
• Sheth S, Macura K. Sonography of the uterine myometrium: Myomas and beyond. Ultrasound Clin. 2007; 2: 267–95
   Google Scholar
• Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. J Occup Environ Med. 2007; 49: 493–506
   PubMed Web of Science ®Google Scholar
• Common AA, Mocarski EJ, Kolin A, Pron G, Soucie J. Therapeutic failure of uterine fibroid embolization caused by underlying leiomyosarcoma. J Vasc Interv Radiol. 2001; 12: 1449–52
   PubMed Web of Science ®Google Scholar
• Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994; 83: 414–8
   PubMed Web of Science ®Google Scholar
• Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003; 101: 243–50
   PubMed Web of Science ®Google Scholar
• Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: A randomized controlled trial. Obstet Gynecol. 2006; 108: 1381–7
   PubMed Web of Science ®Google Scholar
• Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod. 2006; 21: 1869–77
   PubMed Web of Science ®Google Scholar
• Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2006; 91: 1296–304
   PubMed Web of Science ®Google Scholar
• Sasaki H, Ohara N, Xu Q, Wang J, DeManno DA, Chwalisz K, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab. 2007; 92: 616–23
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007; 87: 1399–412
   PubMed Web of Science ®Google Scholar
• Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod. 2007; 22: 1696–704
   PubMed Web of Science ®Google Scholar
• Chillik C, Acosta A. The role of LHRH agonists and antagonists. Reprod Biomed Online. 2001; 2: 120–8
   PubMedGoogle Scholar
• Georgia Reproductive Specialists. Leiomyomas of the uterus-fibroid tumors. Available at: http://www.ivf.com/fibroid.html (accessed March 10, 2008).
   Google Scholar
• Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD, for the Leuprolide Study Group. Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study Obstet Gynecol. 1991;77:720–5.
   PubMed Web of Science ®Google Scholar
• Chavez NF, Stewart EA. Medical treatment of uterine fibroids. Clin Obstet Gynecol. 2001; 44: 372–84
   PubMed Web of Science ®Google Scholar
• Palomba S, Orio F, Jr, Morelli M, Russo T, Pellicano M, Zupi E, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: A pilot study. J Clin Endocrinol Metab. 2002; 87: 3603–8
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990–1997. Obstet Gynecol. 2002; 99: 229–34
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Harvey SA, Yu Y, Sadler L, Stewart AW. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol. 2006; 194: 711–7
   PubMed Web of Science ®Google Scholar
• Meyers ER, Steege JF. Risk adjustment for complications of hysterectomy: Utility of routinely collected administrative data. Prim Care Update Ob Gyns. 1998; 5: 202–3
   PubMedGoogle Scholar
• Dembek CJ, Pelletier EM, Isaacson KB, Spies JB. Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomectomy for treatment of uterine fibroids. J Vasc Interv Radiol. 2007; 18: 1207–13
   PubMed Web of Science ®Google Scholar
• Tulandi T, Kabli N. Update on management of uterine fibroid. Available at: http://www.obgyn.net/Frontiers_In_Reproductive_Medicine/management_uterine_fibroid.asp (accessed February 29, 2008).
   Google Scholar
• Seracchioli R, Rossi S, Govoni F, Rossi E, Venturoli S, Bulletti C, et al. Fertility and obstetric outcome after laparoscopic myomectomy of large myomata: A randomized comparison with abdominal myomectomy. Hum Reprod. 2000; 15: 2663–8
   PubMed Web of Science ®Google Scholar
• Parker WH. Laparoscopic myomectomy and abdominal myomectomy. Clin Obstet Gynecol. 2006; 49: 789–97
   PubMed Web of Science ®Google Scholar
• Kongnyuy EJ, Wiysonge CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2007; CD005355.
   Google Scholar
• Dumousset E, Chabrot P, Rabischong B, Mazet N, Nasser S, Darcha C, et al. Preoperative uterine artery embolization (PUAE) before uterine fibroid myomectomy. Cardiov Intervent Radiol. 2008; 31: 514–20
   PubMed Web of Science ®Google Scholar
• Doridot V, Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K. Recurrence of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 2001; 8: 495–500
   PubMedGoogle Scholar
• Hanafi M. Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol. 2005; 105: 877–81
   PubMed Web of Science ®Google Scholar
• Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril. 2005; 83: 1–23
   PubMed Web of Science ®Google Scholar
• Reproductive Science Center of the San Francisco Bay Area. Laparoscopic/hysteroscopic myomectomy. Available at: http://www.drgalen.com/myomectomy.html (accessed February 29, 2008).
   Google Scholar
• Goldman EL. Laparoscopic myomectomy may save $300/case – Analysis Compares Costs to Open Procedure. Available at: http://findarticles.com/p/articles/mi_m0CYD/is_4_37/ai_83530607 (accessed February 29, 2008).
   Google Scholar
• Subramanian S, Clark MA, Isaacson K. Outcome and resource use associated with myomectomy. Obstet Gynecol. 2001; 98: 583–7
   PubMed Web of Science ®Google Scholar
• Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. Laparoscopic leiomyoma coagulation. J Am Assoc Gynecol Laparosc. 1996; 3: S39
   Google Scholar
• Zupi E, Piredda A, Marconi D, Townsend D, Exacoustos C, Arduini D, et al. Directed laparoscopic cryomyolysis: A possible alternative to myomectomy and/or hysterectomy for symptomatic leiomyomas. Am J Obstet Gynecol. 2004; 190: 639–43
   PubMed Web of Science ®Google Scholar
• Zupi E, Marconi D, Sbracia M, Exacoustos C, Piredda A, Sorrenti G, et al. Directed laparoscopic cryomyolysis for symptomatic leiomyomata: One-year follow up. J Minim Invasive Gynecol. 2005; 12: 343–6
   PubMed Web of Science ®Google Scholar
• Kroencke TJ, Scheurig C, Kluner C, Taupitz M, Schnorr J, Hamm B. Uterine fibroids: Contrast-enhanced MR angiography to predict ovarian artery supply – initial experience. Radiology. 2006; 241: 181–9
   PubMed Web of Science ®Google Scholar
• Burbank F, Hutchins FL, Jr. Uterine artery occlusion by embolization or surgery for the treatment of fibroids: A unifying hypothesis-transient uterine ischemia. J Am Assoc Gynecol Laparosc 2000; 47 Suppl: S1–S49
   Google Scholar
• Sharp HT. Assessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomata. Obstet Gynecol. 2006; 108: 990–1003
   PubMed Web of Science ®Google Scholar
• Myers ER, Goodwin S, Landow W, Mauro M, Peterson E, Pron G, et al. Prospective data collection of a new procedure by a specialty society: The FIBROID registry. Obstet Gynecol. 2005; 106: 44–51
   PubMed Web of Science ®Google Scholar
• Spies JB, Myers ER, Worthington-Kirsch R, Mulgund J, Goodwin S, Mauro M. The FIBROID Registry: Symptom and quality-of-life status 1 year after therapy. Obstet Gynecol. 2005; 106: 1309–18
   PubMed Web of Science ®Google Scholar
• Smith WJ, Upton E, Shuster EJ, Klein AJ, Schwartz ML. Patient satisfaction and disease specific quality of life after uterine artery embolization. Am J Obstet Gynecol. 2004; 190: 1697–703
   PubMed Web of Science ®Google Scholar
• Spies JB, Warren EH, Mathias SD, Walsh SM, Roth AR, Pentecost MJ. Uterine fibroid embolization: Measurement of health-related quality of life before and after therapy. J Vasc Interv Radiol. 1999; 10: 1293–303
   PubMed Web of Science ®Google Scholar
• Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 years’ outcome from the randomized EMMY trial. Am J Obstet Gynecol. 2007; 196: 519e1–519.e11
   Web of Science ®Google Scholar
• Worthington-Kirsch R, Spies JB, Myers ER, Mulgund J, Mauro M, Pron G, et al. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: Short-term outcomes. Obstet Gynecol. 2005; 106: 52–9
   PubMed Web of Science ®Google Scholar
• Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol. 2002; 100: 873–80
   PubMed Web of Science ®Google Scholar
• Hehenkamp WJ, Volkers NA, Donderwinkel PF, de BS, Birnie E, Ankum WM, et al. Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): peri- and postprocedural results from a randomized controlled trial. Am J Obstet Gynecol. 2005; 193: 1618–29
   PubMed Web of Science ®Google Scholar
• Al-Fozan H, Tulandi T. Factors affecting early surgical intervention after uterine artery embolization. Obstet Gynecol Surv. 2002; 57: 810–5
   PubMed Web of Science ®Google Scholar
• Chrisman HB, Saker MB, Ryu RK, Nemcek AA, Jr, Gerbie MV, Milad MP, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol. 2000; 11: 699–703
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Uterine artery embolization. ACOG Committee Opinion No. 293. Obstet Gynecol. 2004;103:403–4.
   PubMed Web of Science ®Google Scholar
• Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, et al. Loss of ovarian reserve after uterine artery embolization: A randomized comparison with hysterectomy. Hum Reprod. 2007; 22: 1996–2005
   PubMed Web of Science ®Google Scholar
• Walker WJ, McDowell SJ. Pregnancy after uterine artery embolization for leiomyomata: A series of 56 completed pregnancies. Am J Obstet Gynecol. 2006; 195: 1266–71
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Heavy menstrual bleeding. Clinical guideline CG44. Available at: http://www.nice.org.uk/guidance/CG44 (accessed July 24, 2007).
   Google Scholar
• Lichtinger M, Hallson L, Calvo P, Adeboyejo G. Laparoscopic uterine artery occlusion for symptomatic leiomyomas. J Am Assoc Gynecol Laparosc. 2002; 9: 191–8
   PubMedGoogle Scholar
• Holub Z, Jabor A, Lukac J, Kliment L, Urbanek S. Midterm follow-up study of laparoscopic dissection of uterine vessels for surgical treatment of symptomatic fibroids. Surg Endosc. 2004; 18: 1349–53
   PubMed Web of Science ®Google Scholar
• Hald K, Klow NE, Qvigstad E, Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: A randomized controlled trial. Obstet Gynecol. 2007; 109: 20–7
   PubMed Web of Science ®Google Scholar
• Hald K, Langebrekke A, Klow NE, Noreng HJ, Berge AB, Istre O. Laparoscopic occlusion of uterine vessels for the treatment of symptomatic fibroids: Initial experience and comparison to uterine artery embolization. Am J Obstet Gynecol. 2004; 190: 37–43
   PubMed Web of Science ®Google Scholar
• Holub Z, Eim J, Jabor A, Hendl A, Lukac J, Kliment L. Complications and myoma recurrence after laparoscopic uterine artery occlusion for symptomatic myomas. J Obstet Gynaecol Res. 2006; 32: 55–62
   PubMed Web of Science ®Google Scholar
• Fibroid FAQs: Guided FUS Procedure, Uterine Cramping, Treatment Descriptions. What types of fibroids can be treated with the ExAblate 2000? Available at: http://www.uterine-fibroids.org/faq.html#8 (accessed February 27, 2008).
   Google Scholar
• Stewart EA, Gedroyc WM, Tempany CM, Quade BJ, Inbar Y, Ehrenstein T, et al. Focused ultrasound treatment of uterine fibroid tumors: Safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol. 2003; 189: 48–54
   PubMed Web of Science ®Google Scholar
• Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril. 2006; 85: 22–9
   PubMed Web of Science ®Google Scholar
• Dickner SK, Cooper JM, Diaz D. A nonincisional, Doppler-guided transvaginal approach to uterine artery identification and control of uterine perfusion. J Am Assoc Gynecol Laparosc. 2004; 11: 55–8
   PubMedGoogle Scholar
• Lichtinger M, Herbert S, Memmolo A. Temporary, transvaginal occlusion of the uterine arteries: A feasibility and safety study. J Minim Invasive Gynecol. 2005; 12: 40–2
   PubMed Web of Science ®Google Scholar
• Istre O, Hald K, Qvigstad E. Multiple myomas treated with a temporary, noninvasive, Doppler-directed, transvaginal uterine artery clamp. J Am Assoc Gynecol Laparosc. 2004; 11: 273–6
   PubMedGoogle Scholar
• Vilos GA, Vilos EC, Romano W, Abu-Rafea B. Temporary uterine artery occlusion for treatment of menorrhagia and uterine fibroids using an incisionless Doppler-guided transvaginal clamp: Case report. Hum Reprod. 2006; 21: 269–71
   PubMed Web of Science ®Google Scholar
• Vilos GA, Lichtinger M. Transvaginal Doppler-guided uterine artery occlusion for the management of leiomyomata uteri: Initial pilot study results. J Minim Invasive Gynecol. 2007; 14: S104
   Google Scholar
• Law P, Regan L. Interstitial thermo-ablation under MRI guidance for the treatment of fibroids. Curr Opin Obstet Gynecol. 2000; 12: 277–82
   PubMed Web of Science ®Google Scholar
• Luo X, Shen Y, Song WX, Chen PW, Xie XM, Wang XY. Pathologic evaluation of uterine leiomyoma treated with radiofrequency ablation. Int J Gynaecol Obstet. 2007; 99: 9–13
   PubMed Web of Science ®Google Scholar
• Bergamini V, Ghezzi F, Cromi A, Bellini G, Zanconato G, Scarperi S, et al. Laparoscopic radiofrequency thermal ablation: A new approach to symptomatic uterine myomas. Am J Obstet Gynecol. 2005; 192: 768–73
   PubMed Web of Science ®Google Scholar
• Ghezzi F, Cromi A, Bergamini V, Scarperi S, Bolis P, Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc. In press.
   Google Scholar
• Kim HS, Tsai J, Jacobs MA, Kamel IR. Percutaneous image-guided radiofrequency thermal ablation for large symptomatic uterine leiomyomata after uterine artery embolization: A feasibility and safety study. J Vasc Interv Radiol. 2007; 18: 41–8
   PubMed Web of Science ®Google Scholar